Study: Once-a-day Pill prevents H.I.V. among Drug Addicts


Study Shows Pill Prevents H.I.V. Among Drug Addicts

Drug-injecting addicts who took a daily antiretroviral pill were half as likely to become infected with H.I.V. as those who did not, a major new study has found, providing the final piece of evidence that such treatments can prevent AIDS in every group at risk. Earlier clinical trials showed that the therapy can sharply reduce the risk of H.I.V. transmission from mother to child, and in gay and bisexual men and heterosexuals.

http://www.nytimes.com/2013/06/13/health/pill-prevents-hiv-among-drug-addicts-in-a-study.html?_r=0

Once-a-day pill prevents HIV in drug users

A once-a-day pill can protect people who inject drugs such as heroin from the AIDS virus, lowering their risk by nearly 50 percent, researchers reported Wednesday.

The findings show that even people at the highest risk of being infected with the virus can protect themselves – and thus protect others. And it adds ammunition to arguments that HIV drugs should be made widely available to fight the epidemic that has killed more than 25 million people.

http://vitals.nbcnews.com/_news/2013/06/12/18921852-once-a-day-pill-prevents-hiv-in-drug-users?lite

HIV prevention pill now recommended for injectable drug users

“This study completes the picture of PrEP efficacy for all major HIV risk groups — we now know that pre-exposure prophylaxis can be a potentially vital option for HIV prevention in people at very high risk for infection, whether through sexual transmission or injecting drug use,” Dr. Michael Martin, chief of clinical research for the Thailand Ministry of Public Health-U.S. CDC Collaboration, said in a news release.

http://www.cbsnews.com/8301-204_162-57589030/hiv-prevention-pill-now-recommended-for-injectable-drug-users/

Daily Pill Cuts HIV Risk in IV Drug Users

The researchers enrolled 2,413 volunteers — ages 20 through 60, HIV-negative, and reporting injecting drugs within the previous 12 months — from 17 drug-treatment clinics in Bangkok.

Study participants were randomly assigned on a one-to-one basis to either tenofovir or placebo and followed for an average of 4 years. They were offered condoms and methadone treatment and got monthly HIV testing, combined with risk-reduction and adherence counseling and blood safety tests every 3 months.

http://www.medpagetoday.com/HIVAIDS/HIVAIDS/39807

Did you already share this? No? Share it now: